Ondosis Revenue and Competitors

Changing the game, one dose at the time OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as microparticles. We are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes. The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal. OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden. The company is a spin-out from AstraZeneca, using technology based on development work initiated there. Founding partners were GU Ventures and Martin Olovsson. Today, OnDosis is owned together with a number of investors, and operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.